stockrowPacira BioSciences, Inc.
PCRX Healthcare Drug Manufacturers Specialty & Generic
Pacira BioSciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $726.4 million, up 3.63% from fiscal 2024.
- Revenue
- −1.59%
- EPS
- +500.0%
- Free cash flow
- −18.5%
- Total debt
- −37.4%
Quarter to September 2026, against a year earlier
Follow PCRX
Alert me
Pacira BioSciences, Inc. (PCRX) EV/Sales
As of 5 November 2026, Pacira BioSciences, Inc. (PCRX) trades at a EV/Sales of 2.3×. Over the past ten years it has ranged from 1.1× (August 2024) to 20.5× (February 2015); the current reading is higher than 22% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of 2.9× and below the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 2.1× | 47.88% |
| FY2024 | 1.4× | (45.68%) |
| FY2023 | 2.6× | (21.55%) |
| FY2022 | 3.3× | (34.87%) |
| FY2021 | 5.0× | (14.20%) |
| FY2020 | 5.8× | 29.06% |
| FY2019 | 4.5× | (8.72%) |
| FY2018 | 4.9× | (21.63%) |
| FY2017 | 6.3× | 41.71% |
| FY2016 | 4.5× | (58.13%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 1.7× | (3.21%) |
| Jun 2026 | 1.8× | 1.05% |
| Mar 2026 | 1.7× | (14.90%) |
| Dec 2025 | 2.1× | 0.15% |
| 43 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| PAHC Phibro Animal Health Corporation compare | 1.4× |
| ANIP ANI Pharmaceuticals, Inc. compare | 1.6× |
| AMPH Amphastar Pharmaceuticals, Inc. compare | 2.0× |
| PCRX Pacira BioSciences, Inc. | 2.3× |
| CRON Cronos Group Inc. compare | 3.0× |
| HROW Harrow, Inc. compare | 4.3× |
| XERS Xeris Biopharma Holdings, Inc. compare | 6.7× |
| ALVO Alvotech compare | 8.6× |
| ETON Eton Pharmaceuticals, Inc. compare | 9.4× |
| Drug Manufacturers Specialty & Generic industry median | 2.9× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)